Communiqués Summit Therapeutics Inc.

Actions

SMMT

US86627T1088

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 16:24:14 18/09/2026			Varia. 5j.	Varia. 1 janv.
17,36 ^USD	-2,03 %		-0,88 %	-0,54 %

15/09	Summit Therapeutics présente les données actualisées de l'étude HARMONi lors de la WCLC 2026, démontrant des résultats de survie globale cohérents avec l'ivonescimab plus chimiothérapie chez les patients occidentaux et asiatiques	CI
14/09	L'action Summit Therapeutics progresse après les résultats de survie de l'étude de phase 3 d'Akeso sur l'ivonescimab dans le cancer du poumon en Chine	MT

Communiqués

15/09	Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients	BU
13/09	Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China	BU
02/09	Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China	BU
26/08	Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China	BU
25/08	Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology	BU
13/08	Summit Therapeutics - Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer	AQ
12/08	Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer	BU
05/08	Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer	BU
27/07	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026	AQ
23/07	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026	BU
22/07	Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study	BU
16/07	Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026	BU
14/07	Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.	BU
09/06	Summit Therapeutics Announces Proposed Public Offering of Common Stock	BU
04/06	Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference	BU
31/05	Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the Phase 3 HARMONi-6 Slides	PU
31/05	Summit Therapeutics : Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China	PU
31/05	Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China	BU
30/05	A randomized, active-controlled phase 3 study of ivonescimab FOLFOX versus bevacizumab FOLFOX as first-line treatment of metastatic colorectal cancer: HARMONi-GI3	PU
30/05	Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026	BU
30/04	Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026	BU
27/03	Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy	PU
27/03	Health-Related Quality of Life With Ivonescimab Versus Pembrolizumab for PD-L1 Positive, Non–Small Cell Lung Cancer (HARMONi-2): A Randomised, Double-Blind, Phase 3 Study in China	PU
27/03	Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026	BU
27/02	Summit Therapeutics to Present at Upcoming Investor Conferences	BU